influenza
virus
b
main
pathogen
respons
onset
epidem
evolv
natur
rna
virus
high
mutat
rate
abil
make
drift
chang
howev
influenza
virus
respons
pandem
worldwid
influenza
virus
caus
sever
infect
million
peopl
annual
viral
infect
kill
million
peopl
influenza
outbreak
produc
high
morbid
mortal
rate
great
econom
social
earli
find
relat
recent
influenza
pandem
occur
april
mexico
soon
spread
countri
pandem
caus
variant
came
two
genet
recombin
event
first
occur
avian
viru
american
pig
viru
viru
fragment
human
exchang
genet
materi
follow
recombin
european
swine
viru
strain
result
pandem
swine
origin
influenza
mexico
recent
year
caus
least
four
outbreak
high
mortal
rate
compar
present
winter
influenza
activ
increas
mexico
case
influenza
death
confirm
march
case
case
case
b
remain
six
case
result
eman
differ
studi
shown
influenza
outbreak
character
high
sever
symptom
increas
sever
factor
associ
diseas
sever
factor
due
viru
ie
viral
pathogen
mutat
resist
antivir
factor
inher
host
suscept
eg
age
sex
race
includ
physiolog
immunosuppress
acquir
diseas
ie
diabet
hypertens
obes
asthma
factor
associ
avail
medic
servic
public
health
facil
factor
aris
presenc
bacteri
season
pandem
influenza
often
complic
aris
bacteri
coinfect
et
document
patient
communityacquir
pneumonia
frequent
isol
bacteri
pathogen
streptococcu
pneumonia
pseudomona
aeruginosa
staphylococcu
aureu
rare
found
haemophilu
influenza
pandem
death
bacteri
coinfect
global
influenza
viru
infect
need
intens
care
among
hospit
patient
case
influenza
correspond
healthi
young
individu
least
total
case
elderli
group
coinfect
harbor
symptom
influenza
case
bacteri
coinfect
similar
sever
influenza
former
may
higher
risk
death
identif
coinfect
consid
patient
influenzalik
ill
ili
present
symptom
suggest
pneumonia
dyspnea
tachypnea
hypoxia
evid
mani
copathogen
known
colon
respiratori
mucosa
ie
pneumonia
h
influenza
neisseria
meningitidi
includ
upper
lower
respiratori
tract
distinct
copathogen
colon
coinfect
critic
proven
coinfect
clinic
correl
sign
pneumonia
bacteri
contagion
produc
increas
acuiti
sever
empir
antivir
treatment
consid
manag
critic
ill
patient
commonli
isol
bacteri
pathogen
colon
nasopharynx
complex
contribut
significantli
pathogenesi
diseas
mainli
period
endem
studi
report
copathogen
influenza
virus
case
observ
produc
sever
complic
two
studi
hypothes
viral
interfer
suggest
rhinoviru
infect
may
interfer
influenza
still
fulli
precis
identif
infecti
pathogen
respons
acut
respiratori
infect
primarili
influenza
critic
factor
proper
treatment
diseas
control
outbreak
appropri
use
antibiot
antivir
reason
continu
investig
pathogen
commonli
associ
influenza
case
urgent
need
presenc
bacteri
viral
copathogen
identifi
use
clinic
sampl
molecular
diagnosi
resequenc
microarray
studi
patient
confirm
influenza
oaxaca
mexico
also
document
associ
influenza
symptom
diseas
sever
dead
patient
multiplemicrobi
infect
present
studi
involv
collabor
one
govern
health
institut
mexico
perform
sampl
collect
examin
adult
voluntarili
come
examin
point
agre
particip
inform
microbiolog
process
hisher
sampl
oral
consent
obtain
parent
guardian
provid
oral
consent
behalf
age
child
particip
ethic
committe
health
secretariat
mexico
approv
use
oral
consent
given
studi
conduct
part
nation
program
thu
part
routin
public
healthmonitor
program
conduct
mexican
govern
total
studi
patient
confirm
quantit
qrtpcr
six
health
district
oaxaca
mexico
examin
microbi
infect
patient
recruit
april
throughout
decemb
present
studi
meet
oper
definit
criteria
ili
case
recommend
world
health
particip
confirm
qrtpcr
ili
age
fever
cough
headach
accompani
one
rhinorrhea
rhiniti
arthralgia
myalgia
prostrat
sore
throat
chest
pain
abdomin
pain
nasal
congest
includ
studi
patient
year
age
irrit
substitut
headach
year
age
fever
requir
cardin
symptom
individu
respiratori
clinic
sampl
collect
includ
throat
swab
nasopharyng
swab
bronchoalveolar
lavag
lung
biopsi
accord
patient
condit
throat
nasopharyng
swab
collect
use
rayon
dacron
hyssop
plastic
tube
contain
ml
viral
transport
medium
bronchoalveolar
wash
lung
biopsi
sampl
collect
train
medic
staff
place
plastic
bottl
contain
ml
viral
transport
medium
sampl
kept
sampl
transport
local
molecular
biolog
laboratori
store
viral
rna
extract
use
clinic
sampl
posit
control
influenza
donat
laboratori
molecular
valid
test
institut
epidemiolog
diagnosi
refer
mexico
follow
manufactur
instruct
qiaamp
viral
rna
minikit
qiagen
venlo
netherland
rna
extract
complet
use
autom
protocol
qiacub
qiagen
elut
volum
rna
use
templat
store
test
protocol
includ
four
set
primer
probe
univers
influenza
infa
swine
flu
swinfa
swine
rnase
p
rp
primer
taqman
primer
probe
synthes
biosearch
technolog
novato
ca
usa
tabl
follow
us
center
diseas
control
prevent
protocol
http
use
fast
abi
thermocycl
thermo
fisher
scientif
waltham
usa
total
reaction
volum
includ
templat
dna
primer
forward
revers
primer
probe
pcr
master
mix
superscript
iii
rtplatinum
taq
mix
steril
molecular
biolog
grade
water
pcr
procedur
start
one
cycl
minut
rt
one
cycl
minut
taq
inhibitor
activ
follow
cycl
second
second
fluoresc
data
need
collect
incub
step
posit
control
neg
control
molecular
biolog
grade
water
run
parallel
experi
background
fluoresc
consid
correct
valu
cycl
threshold
cut
ct
thu
consid
threshold
went
background
fluoresc
run
exponenti
phase
amplif
curv
cutoff
valu
correct
accordingli
primari
sampl
total
nucleic
acid
recov
follow
manufactur
instruct
masterpur
dna
rnaisol
kit
epicentr
biotechnolog
madison
wi
usa
final
elut
volum
store
test
amount
total
nucleic
acid
estim
accord
ratio
nm
use
nanodrop
thermo
fisher
scientif
rpmflu
rt
tube
contain
total
nucleic
acid
rt
perform
order
obtain
cdna
rt
master
mix
compris
buffer
singl
chain
dtt
rnaseout
superscript
iii
rtplatinum
taq
mix
rtpcr
cycl
condit
minut
minut
minut
result
product
store
four
rpmflu
multiplex
pcr
tube
b
c
multiplex
pcr
amplif
conduct
reaction
mixtur
contain
cdna
flexi
buffer
gotaq
mm
dna
polymeras
gotaq
udg
pcr
cycl
condit
initi
two
cycl
minut
minut
follow
cycl
second
second
increas
everi
cycl
second
reaction
end
use
cycl
second
minut
pcr
product
store
reagent
use
fragment
label
pcr
product
resequenc
genechip
assay
affymetrix
thermo
fisher
scientif
briefli
pcr
tube
fragment
conduct
use
purifi
pcr
product
master
mix
fragment
buffer
fragment
reagent
pcr
cycl
condit
minut
minut
pcr
product
store
subsequ
new
pcr
tube
use
perform
dna
label
contain
fragment
pcr
product
master
mix
tdt
buffer
label
reagent
tdt
pcr
cycl
condit
minut
minut
label
pcr
product
place
least
minut
hybrid
hybrid
procedur
carri
hour
use
hybrid
oven
model
affymetrix
microarray
wash
stain
affymetrix
fluidic
station
comput
cel
file
contain
microarray
imag
produc
affymetrix
scanner
scan
imag
microarray
analyz
use
gseq
softwar
produc
chp
file
contain
name
sequenc
identifi
sampl
sequenc
store
fasta
file
submit
onlin
retest
sequenc
manufactur
websit
http
sequenc
pathogen
identifi
fasta
file
contain
result
posit
neg
control
overview
sequenc
includ
name
score
homolog
percentag
length
longest
continu
sequenc
patient
data
age
sex
date
flu
symptom
clinic
sampl
date
place
resid
captur
excel
spreadsheet
proport
patient
microbi
infect
calcul
number
posit
patient
divid
total
number
examin
express
percentag
preval
associ
ci
proport
patient
harbor
pathogen
also
determin
preval
patient
influenza
copathogen
addit
one
five
pathogen
examin
signific
differ
indic
overlap
ci
preval
pathogen
symptom
patient
also
examin
per
agegroup
influenza
viru
detect
confirm
qrtpcr
total
clinic
sampl
studi
patient
show
ili
oaxaca
mexico
tabl
identifi
associ
pathogen
sampl
use
microarray
rpmflu
total
patient
present
copathogen
bacteria
andor
virus
influenza
tabl
patient
patient
harbor
singl
pathogen
influenza
harbor
two
pathogen
harbor
three
pathogen
two
harbor
four
pathogen
one
harbor
five
pathogen
preval
copathogen
vari
among
patient
coinfect
one
three
pathogen
howev
significantli
p
low
number
patient
coharbor
four
five
pathogen
tabl
genera
associ
bacteri
pathogen
identifi
streptococcu
haemophilu
neisseria
pseudomona
staphylococcu
klebsiella
moraxella
well
parainfluenza
coinfect
coxsacki
virus
preval
speci
bacteria
found
p
pneumonia
h
influenza
n
meningitidi
miti
figur
medium
number
preval
bacteria
p
aeruginosa
patient
rang
preval
harbor
speci
bacteria
h
parainfluenza
aureu
p
putida
p
mendocina
n
gonorrhoea
less
preval
speci
bacteria
virus
found
also
summar
figur
tabl
highlight
copathogen
identifi
colon
respiratori
tract
coinfect
pathogen
found
patient
oaxaca
symptom
identifi
common
fever
patient
impair
gener
health
cough
headach
myalgia
rhinorrhea
odynophagia
cold
nasal
congest
sign
andor
symptom
found
among
studi
particip
year
old
infect
influenza
microbi
infect
figur
six
patient
experienc
diseas
sever
admit
intens
care
unit
tabl
two
four
dead
patient
harbor
three
bacteria
one
male
age
year
pneumonia
h
influenza
n
meningitidi
treat
outpati
basi
present
symptom
fever
impair
gener
health
odynophagia
cough
headach
femal
aureu
miti
pneumonia
multipl
symptom
tabl
die
period
confin
puerperium
childbirth
remain
two
dead
patient
harbor
two
bacteria
one
male
age
year
pneumonia
n
gonorrhoea
treat
outpati
basi
present
multipl
symptom
asthmat
one
male
h
influenza
miti
babi
present
multipl
symptom
also
asthmat
mexico
suffer
least
four
outbreak
produc
influenza
viru
higher
mortal
rate
report
mention
viral
host
timeli
medic
treatment
presenc
associ
increas
sever
diseas
caus
viru
among
factor
may
explain
epidemiolog
scenario
mexico
first
outbreak
viru
mexico
increas
mortal
note
presenc
coinfect
therefor
paramount
import
investig
organ
caus
coinfect
implement
monitor
surveil
system
diseas
mexico
use
standard
qrtpcr
protocol
identifi
influenza
viru
conjunct
microarray
assay
detect
associ
pathogen
posit
patient
influenza
microarray
assay
shown
capabl
detect
singl
sampl
virus
bacteria
may
produc
identif
pathogen
base
sequenc
analysi
subsequ
search
genbank
databas
help
identifi
specif
viral
type
speci
bacteria
present
significantli
high
preval
rate
influenza
patient
one
three
associ
pathogen
tabl
bacteria
speci
frequent
identifi
pneumonia
total
individu
copathogen
differ
somewhat
percentag
report
h
influenza
n
meningitidi
also
show
high
preval
rate
n
meningitidi
associ
greater
sever
ill
requir
process
immunosuppress
associ
pathogen
present
elev
preval
rate
miti
p
aeruginosa
coincid
studi
report
coinfect
howev
compar
result
studi
previou
studi
prudenc
exercis
given
anatom
site
sampl
techniqu
detect
sensit
specif
somewhat
differ
noteworthi
presenc
high
number
patient
harbor
sever
pathogen
produc
respiratori
infect
explain
consid
sanitari
condit
particular
countri
exampl
preval
meningococc
diseas
vari
among
countri
case
per
addit
three
case
pandem
viru
found
coinfect
parainfluenza
coxsacki
viru
result
studi
consist
studi
report
lower
rate
viral
coinfect
respiratori
syncyti
viru
coronaviru
influenza
b
viru
adenoviru
parainfluenza
viru
without
signific
complic
increas
sever
similarli
associ
found
patient
certain
sign
andor
symptom
influenza
alon
pathogen
tabl
although
tabl
address
sever
ill
indic
treatment
bacteri
infect
necessari
evolut
clinic
statu
patient
sever
patient
interestingli
harbor
copathogen
six
patient
group
admit
intens
care
unit
four
die
consequ
male
could
die
consequ
infect
n
meningitidi
influenza
could
facilit
meningococc
femal
puerperium
present
symptom
three
pathogen
bacteria
aureu
one
studi
found
major
aureu
isol
children
adult
methicillin
consequ
treat
inpati
intens
care
unit
two
dead
patient
asthmat
presum
die
adult
children
asthma
like
develop
pneumonia
get
sick
flu
peopl
asthma
http
pdf
male
harbor
pneumonia
appear
synergist
relationship
patient
treat
inpati
basi
sent
intens
care
unit
asthmat
present
differ
symptom
howev
treat
outpati
basi
male
eight
symptom
harbor
miti
could
elev
risk
exacerb
influenza
total
patient
harbor
miti
patient
complic
submit
intens
care
unit
treat
neuraminidas
inhibitor
oseltamivir
tamiflu
within
hour
first
symptom
infect
increas
number
miti
case
could
also
hamper
efficaci
viral
neuraminidas
inhibitor
four
patient
die
miti
present
three
copathogen
found
signific
number
influenza
case
oaxaca
although
copathogen
may
simpli
asymptomat
colon
bacteria
manifest
proven
coinfect
diseas
sever
patient
given
copathogen
found
commonli
could
impact
diseas
studi
need
conduct
eg
investig
coinfect
pandem
viru
pathogen
sourc
secondari
infect
patient
statu
immunosuppress
moreov
factor
explain
increas
sever
symptom
mortal
rate
caus
oaxaca
note
area
oaxaca
sanitari
condit
adequ
may
allow
prolifer
pathogen
agent
detect
monitor
surveil
system
base
molecular
diagnost
respiratori
pathogen
implement
well
strengthen
sanitari
measur
local
oaxaca
popul
urgent
need
